Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabienne Thomas

Showing results (21-30 of 83) with videos related to

Pageof 9
Sort By:
Therapie|February 4, 2017
Nicolas Picard, Jean-Christophe Boyer, Marie-Christine Etienne-Grimaldi, et al.
Therapie|February 27, 2017
Pharmacogenetics-based personalized therapy: Levels of evidence and recommendations from the French Network of Pharmacogenetics (RNPGx)Nicolas Picard, Jean-Christophe Boyer, Marie-Christine Etienne-Grimaldi, et al.
Cancer Chemotherapy and Pharmacology|June 21, 2018
Therapeutic drug monitoring and dose adaptation of cisplatin in a newborn with hepatoblastoma: a case reportFabienne Thomas, Gareth J Veal, Souleiman El Balkhi, et al.
Cancer Research|April 4, 2022
Correction: Hypoxia Drives Dihydropyrimidine Dehydrogenase Expression in Macrophages and Confers Chemoresistance in Colorectal CancerMarie Malier, Khaldoun Gharzeddine, Marie-Hélène Laverriere, et al.
Pharmacogenomics|September 13, 2013
Irreversible hepatotoxicity after administration of trabectedin to a pleiomorphic sarcoma patient with a rare ABCC2 polymorphism: a case reportAnne-Pascale Laurenty, Fabienne Thomas, Etienne Chatelut, et al.
Head & Neck|July 14, 2012
Gene expression profiling on pre- and post-erlotinib tumors from patients with head and neck squamous cell carcinomaFabienne Thomas, Paul Delmar, Sébastien Vergez, et al.
Investigational New Drugs|November 18, 2015
Determination of unbound fraction of pazopanib in vitro and in cancer patients reveals albumin as the main binding siteDiane-Charlotte Imbs, Marie-Noelle Paludetto, Sylvie Négrier, et al.
Clinical Chemistry and Laboratory Medicine|August 14, 2024
Reply to: "Is uracil enough for effective pre-emptive DPD testing?"Fabienne Thomas, Manon Launay, Laure Raymond, et al.
Chemotherapy|October 13, 2024
Therapeutic Drug Monitoring of Imatinib: Is There a Rationale for Also Quantifying Its Active Metabolite?Clara Eschalier, Thierry Lafont, Sabrina Marsili, et al.
Clinical Chemistry and Laboratory Medicine|June 19, 2024
Can we identify patients carrying targeted deleterious <i>DPYD</i> variants with plasma uracil and dihydrouracil? A GPCO-RNPGx retrospective analysisManon Launay, Laure Raymond, Jérôme Guitton, et al.
Pageof 9

Showing results (21-30 of 83) with videos related to

Sort By:
Pageof 9
Therapie|February 4, 2017
Nicolas Picard, Jean-Christophe Boyer, Marie-Christine Etienne-Grimaldi, et al.
Therapie|February 27, 2017
Pharmacogenetics-based personalized therapy: Levels of evidence and recommendations from the French Network of Pharmacogenetics (RNPGx)Nicolas Picard, Jean-Christophe Boyer, Marie-Christine Etienne-Grimaldi, et al.
Cancer Chemotherapy and Pharmacology|June 21, 2018
Therapeutic drug monitoring and dose adaptation of cisplatin in a newborn with hepatoblastoma: a case reportFabienne Thomas, Gareth J Veal, Souleiman El Balkhi, et al.
Cancer Research|April 4, 2022
Correction: Hypoxia Drives Dihydropyrimidine Dehydrogenase Expression in Macrophages and Confers Chemoresistance in Colorectal CancerMarie Malier, Khaldoun Gharzeddine, Marie-Hélène Laverriere, et al.
Pharmacogenomics|September 13, 2013
Irreversible hepatotoxicity after administration of trabectedin to a pleiomorphic sarcoma patient with a rare ABCC2 polymorphism: a case reportAnne-Pascale Laurenty, Fabienne Thomas, Etienne Chatelut, et al.
Head & Neck|July 14, 2012
Gene expression profiling on pre- and post-erlotinib tumors from patients with head and neck squamous cell carcinomaFabienne Thomas, Paul Delmar, Sébastien Vergez, et al.
Investigational New Drugs|November 18, 2015
Determination of unbound fraction of pazopanib in vitro and in cancer patients reveals albumin as the main binding siteDiane-Charlotte Imbs, Marie-Noelle Paludetto, Sylvie Négrier, et al.
Clinical Chemistry and Laboratory Medicine|August 14, 2024
Reply to: "Is uracil enough for effective pre-emptive DPD testing?"Fabienne Thomas, Manon Launay, Laure Raymond, et al.
Chemotherapy|October 13, 2024
Therapeutic Drug Monitoring of Imatinib: Is There a Rationale for Also Quantifying Its Active Metabolite?Clara Eschalier, Thierry Lafont, Sabrina Marsili, et al.
Clinical Chemistry and Laboratory Medicine|June 19, 2024
Can we identify patients carrying targeted deleterious <i>DPYD</i> variants with plasma uracil and dihydrouracil? A GPCO-RNPGx retrospective analysisManon Launay, Laure Raymond, Jérôme Guitton, et al.
Pageof 9